Home›Trial›NCT06388421
NCT06388421RECRUITING

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study Summary

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Conditions
Pulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary HypertensionInterstitial Lung Disease
Interventions / Drugs
Prospective study assessments
View on ClinicalTrials.gov ↗
Sponsor
UTHR
United Therapeutics
Pulmonary
D35/100
Study Details
Enrollment900 participants
Primary Completion—
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432884+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 900 participants
Sponsor Catalyst Profile

United Therapeutics (UTHR) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

UTHR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.